Some studies have shown that Immune checkpoint inhibitors (ICIs) have a favorable efcacy in advanced triple negative breast cancer (TNBC) patients, but the results are controversial in neoadjuvant chemotherapy (NACT) stage. The purpose of this study is to evaluate the efcacy and safety after NACT plus ICIs in early TNBC patients. |